Dudediligence.

Ligand Pharmaceuticals Incorporated

LGNDNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$51.8MSep ’24$42.8MDec ’24$45.3MMar ’25$47.6MJun ’25$115.5MSep ’25$59.7MDec ’25$51.7MMar ’26$63.7MJun ’26
Net income, by quarter
−$7.2MSep ’24−$31.1MDec ’24−$42.5MMar ’25$4.8MJun ’25$117.3MSep ’25$44.8MDec ’25−$13.3MMar ’26$48.5MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$241.5M$196.2M$131.3M$167.1M$268.1M
Operating income$103.9M$3.0M$11.9M−$22.6M$41.0M
Net income$57.1M−$33.4M$52.2M−$4.0M$124.5M
Operating cash flow$78.8M$137.8M$49.6M$97.0M$49.4M
Free cash flow$70.0M$119.9M$46.1M$95.2M$48.9M
Cash$19.5M$45.0M$23.0M$72.3M$174.9M
Shares outstanding16.8M17.0M17.6M19.1M19.8M